OBJECTIVES: All over the world, different interventions are made by the public decision-maker to effectively use limited resources in health economics.Restriction and prioritization decisions are aimed at equal distribution of fiscal resources and early access to medicine to target patient groups.Demographic pyramid,the incidence of disease, and health economics findings affect the scope of prioritization decision of new molecule.The aim of this study, to compare selected original product reimbursement conditions between FDA,EMA and Türkiye and evaluate on reimbursement decisions of Türkiye for recent years

METHODS: In this study, the approved indications of selected medicines are web-based scanned EMA,FDA,TITCK and SGK websites. Oncology and hyperlidemia treatments have been determined as the study area since oncology and immunology treatment fields are forecasted to grow by 9-12% and 6-9% CAGR by 2026

RESULTS: There are 62 headlines in Healthcare Implementation Communique.28 of them has regulated treatment conditions for specific diagnoses for reimbursement as mentioned in the example of Nivolumab and Evolocumab.Both molecules are monoclonal antibiotherapy.We found out for nivolumab,this delay averaged 1.94 years from FDA and 1.71 years from EMA.Evolocumab has only one approved indication in Türkiye which was approved in Türkiye 10 months and 1.1 years after FDA and EMA respectively. These delays increase even more in the reimbursement processes.Although nivolumab has 11 and 10 different cancer indications approved by the FDA and EMA respectively,there are 7 different cancer indications approved in Türkiye and 4 of them are reimbursed.Although evolocumab has 3 different indications approved in FDA and EMA, Türkiye has 2 approved indications and 1 of them reimbursed

CONCLUSIONS: Certain patient groups have been prioritized with the restrictions made on such medicines, which have high budgetary expectations and these patients' access to treatment has been facilitated.Further studies needs to evaluate access of new treatments and focus on potential benefit for patients’ access to medicines